Finance

Lists
DTIL:NASDAQ
Precision BioSciences Inc
$7.43
+1.78%
(+0.13) 1D
$7.43
0.00% (0.00)
After hours
Closed: Aug 14, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DTIL...
Open
$7.26
High
$7.47
Low
$7.18
Mkt. cap
205.08M
Avg. vol.
404.63K
Volume
142.10K
52-wk high
$9.62
52-wk low
$3.53
EPS
-$2.80
Beta
1.27
Shares outstanding
27.60M
No. of employees
67
Open
$7.26
High
$7.47
Low
$7.18
Mkt. cap
205.08M
Avg. vol.
404.63K
Volume
142.10K
52-wk high
$9.62
52-wk low
$3.53
EPS
-$2.80
Beta
1.27
Shares outstanding
27.60M
No. of employees
67
News stories
From web sources and news partners
Profile
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform. Wikipedia
About Precision BioSciences Inc
CEO-
Employees67
Founded2006
Headquarters-
SectorBiotechnology
Websiteprecisionbiosciences.com
Analyst ratings
Based on 3 analysts giving stock ratings to DTIL in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for DTIL in the last 3 months.
Highest
Current $7.43
$60.00 (+707.54%)
Average
$33.00 (+344.15%)
Lowest
$19.00 (+155.72%)
Analyst
Recommendation
Action
Price target
Projected
Date
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$60.00
+707.5%
08/12/2026
Kostas Biliouris
Oppenheimer
Buy
Initiated
$20.00
+169.2%
06/09/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$19.00
+155.7%
05/28/2026
Catherine Novack
JonesTrading
Buy
Initiated
$30.00
+303.8%
04/16/2026
Unknown Analyst
Guggenheim
Buy
Maintained
$19.00
+155.7%
03/12/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
13.00K
34.20M
10.84M
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
12.67M
14.46M
13.11M
12.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.01M
7.23M
6.80M
6.77M
Operating expense
20.68M
21.70M
19.91M
19.16M
Total operating expenses
20.68M
21.70M
19.91M
19.16M
Operating income
-20.67M
12.51M
-9.08M
-19.16M
Other non operating income
-1.18M
12.11M
-7.11M
-13.89M
EBT including unusual items
-21.77M
19.25M
-18.44M
-32.65M
EBT excluding unusual items
-21.77M
19.67M
-15.49M
-32.41M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-21.77M
20.13M
-18.44M
-32.65M
Net profit margin
-167,476.92%
58.86%
-170.15%
-
Earnings per share
-1.84
1.01
-0.75
-1.26
Interest and investment income
1.03M
773.00K
999.00K
943.00K
Interest expense
-362.00K
-348.00K
-311.00K
-300.00K
Net interest expenses
665.00K
425.00K
688.00K
643.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.32M
12.85M
-8.78M
-18.91M
Gain or loss from assets sale
-3.00K
-465.00K
-4.00K
-1.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps